Effectiveness of brief interventions as part of the screening, brief intervention and referral to treatment (SBIRT) model for reducing the non-medical use of psychoactive substances: a systematic review protocol

Matthew M Young, Adrienne Stevens, Amy Porath-Waller, Tyler Pirie, Chantelle Garritty, Becky Skidmore, Lucy Turner, Cheryl Arratoon, Nancy Haley, Karen Leslie, Rhoda Reardon, Beth Sproule, Jeremy Grimshaw, David Moher, Matthew M Young, Adrienne Stevens, Amy Porath-Waller, Tyler Pirie, Chantelle Garritty, Becky Skidmore, Lucy Turner, Cheryl Arratoon, Nancy Haley, Karen Leslie, Rhoda Reardon, Beth Sproule, Jeremy Grimshaw, David Moher

Abstract

Background: There is a significant public health burden associated with substance use in Canada. The early detection and/or treatment of risky substance use has the potential to dramatically improve outcomes for those who experience harms from the non-medical use of psychoactive substances, particularly adolescents whose brains are still undergoing development. The Screening, Brief Intervention, and Referral to Treatment model is a comprehensive, integrated approach for the delivery of early intervention and treatment services for individuals experiencing substance use-related harms, as well as those who are at risk of experiencing such harm.

Methods: This article describes the protocol for a systematic review of the effectiveness of brief interventions as part of the Screening, Brief Intervention, and Referral to Treatment model for reducing the non-medical use of psychoactive substances. Studies will be selected in which brief interventions target non-medical psychoactive substance use (excluding alcohol, nicotine, or caffeine) among those 12 years and older who are opportunistically screened and deemed at risk of harms related to psychoactive substance use. We will include one-on-one verbal interventions and exclude non-verbal brief interventions (for example, the provision of information such as a pamphlet or online interventions) and group interventions. Primary, secondary and adverse outcomes of interest are prespecified. Randomized controlled trials will be included; non-randomized controlled trials, controlled before-after studies and interrupted time series designs will be considered in the absence of randomized controlled trials. We will search several bibliographic databases (for example, MEDLINE, EMBASE, CINAHL, PsycINFO, CORK) and search sources for grey literature. We will meta-analyze studies where possible. We will conduct subgroup analyses, if possible, according to drug class and intervention setting.

Discussion: This review will provide evidence on the effectiveness of brief interventions as part of the Screening, Brief Intervention, and Referral to Treatment protocol aimed at the non-medical use of psychoactive substances and may provide guidance as to where future research might be most beneficial.

References

    1. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L. Reporting Guidelines for Systematic Review Protocols. Madrid, Spain:In 19th Cochrane Colloquium: October 19–22 2011; 2011.
    1. Health Canada. Canadian Alcohol and Drug Use Monitoring Survey (CADUMS) .
    1. Rehm J, Baliunas D, Brochu S, Fischer B, Gnam W, Patra J, Popova S, Sarnocinska-Hart A, Taylor B. The costs of substance abuse in Canada 2002. Canadian Centre on Substance Abuse, Ottawa, ON; 2006.
    1. Degenhardt L, Hall W, Warner-Smith M, Lynskey M. In: Global and regional burden of diseases attributable to selected major risk factors. 1. Ezzati M, Lopez AD, Rogers A, Murray CJL, editor. World Health Organization, Geneva; 2004. Illicit drug use.
    1. Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. Subst Abus. 2007;28(3):7–30. doi: 10.1300/J465v28n03_03.
    1. Saunders JB, Aasland OG, Babor TF, De La Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption. Part II. Addiction. 1993;88:791–804.
    1. Adamson SJ, Sellman JD. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev. 2003;22(3):309–315. doi: 10.1080/0959523031000154454.
    1. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–442. doi: 10.1111/j.1526-4637.2005.00072.x.
    1. Gavin DR, Ross HE, Skinner HA. Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders. Br J Addict. 1989;84(3):301–307. doi: 10.1111/j.1360-0443.1989.tb03463.x.
    1. Carney T, Myers BJ, Louw J. Brief school-based interventions and behavioural outcomes for substance-using adolescents. Cochrane Database Syst Rev. 2011;2:CD008969.
    1. Kaner EF, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, Heather N, Saunders J, Burnand B. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007;2:CD004148.
    1. McQueen J, Howe TE, Allan L, Mains D, Hardy V. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev. 2011;8:CD005191.
    1. Levy S, Vaughan BL, Knight JR. Office-based intervention for adolescent substance abuse. Pediatr Clin N Am. 2002;49(2):329–343. doi: 10.1016/S0031-3955(01)00007-4.
    1. Kahan M, Wilson L, Becker L. Effectiveness of physician-based interventions with problem drinkers: a review. Canadian Med Assoc J. 1995;152(6):851–859.
    1. Reid MC, Fiellin DA, O'Connor PG. Hazardous and harmful alcohol consumption in primary care. Arch Intern Med. 1999;159(15):1681–1689. doi: 10.1001/archinte.159.15.1681.
    1. Wilk AI, Jensen NM, Havighurst TC. Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. J Gen Int Med. 1997;12(5):274–283. doi: 10.1007/s11606-006-5063-z.
    1. Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abus Treat. 2001;21(2):55–64. doi: 10.1016/S0740-5472(01)00179-9.
    1. Humeniuk R, Ali R, Babor T, Souza-Formigoni ML, de Lacerda RB, Ling W, McRee B, Newcombe D, Pal H, Poznyak V, Simon S, Vendetti J. A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health care settings in four countries. Addiction. 2012;107(5):957–966. doi: 10.1111/j.1360-0443.2011.03740.x.
    1. Lang E, Engelander M, Brooke T. Report of an integrated brief intervention with self-defined problem cannabis users. J Subst Abus Treat. 2000;19(2):111–116. doi: 10.1016/S0740-5472(99)00104-X.
    1. Martin G, Copeland J, Swift W. The Adolescent Cannabis Check-Up: feasibility of a brief intervention for young cannabis users. J Subst Abus Treat. 2005;29(3):207–213. doi: 10.1016/j.jsat.2005.06.005.
    1. McCambridge J, Strang J. The efficacy of single-session motivational interviewing in reducing drug consumption and perceptions of drug-related risk and harm among young people: results from a multi-site cluster randomized trial. Addiction. 2004;99(1):39–52. doi: 10.1111/j.1360-0443.2004.00564.x.
    1. Martin G, Copeland J. Brief intervention for regular ecstasy (MDMA) user: pilot randomized trial of a Check-Up model. J Subs Use. 2010;15(2):131–142. doi: 10.3109/14659890903075074.
    1. Bernstein J, Bernstein E, Tassiopoulos K, Heeren T, Levenson S, Hingson R. Brief motivational intervention at a clinic visit reduces cocaine and heroin use. Drug Alcohol Depend. 2005;77(1):49–59. doi: 10.1016/j.drugalcdep.2004.07.006.
    1. Stotts AL, Schmitz JM, Rhoades HM, Grabowski J. Motivational interviewing with cocaine-dependent patients: a pilot study. J Consult Clin Psychol. 2001;69(5):858–862.
    1. Bashir K, King M, Ashworth M. Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Br J Gen Pract. 1994;44(386):408–412.
    1. Saitz R, Alford DP, Bernstein J, Cheng DM, Samet J, Palfai T. Screening and brief intervention for unhealthy drug use in primary care settings: randomized clinical trials are needed. J Addiction Med. 2010;4(3):123–130. doi: 10.1097/ADM.0b013e3181db6b67.
    1. Walker DD, Roffman RA, Stephens RS, Wakana K, Berghuis J, Kim W. Motivational enhancement therapy for adolescent marijuana users: a preliminary randomized controlled trial. J Consult Clin Psychol. 2006;74(3):628–632.
    1. McCabe SE, Cranford JA, West BT. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav. 2008;33(10):1297–1305. doi: 10.1016/j.addbeh.2008.06.005.
    1. The Cochrane Collaboration. Suggested risk of bias criteria for EPOC reviews. .
    1. Sampson M, McGowan J, Lefebvre C, Moher D, Grimshaw J. PRESS: Peer Review of Electronic Search Strategies. Canadian Agency for Drugs and Technologies in Health, Ottawa, ON; 2008.
    1. Canadian Agency for Drugs and Technologies in Health. Grey Matters: a practical tool for evidence-based searching. .
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269. W264.
    1. the Cochrane Non-Randomised Studies Methods Group; the Cochrane Non-Randomised Studies Methods Group. Chapter 13.5: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor. Cochrane Handbook for Systematic Reviews of Interventions. Volume 5.10. The Cochrane Collaboration; 2011. .
    1. Higgins JPT, Deeks JJ, Altman DG. In: Cochrane Handbook for Systematic Reviews of Interventions. Volume 5.10. Higgins JPT, Green S, editor. The Cochrane Collaboration; 2011. Chapter 16: Special topics in statistics. .
    1. Killip S, Mahfoud Z, Pearce K. What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. Ann Fam Med. 2004;2(3):204–208. doi: 10.1370/afm.141.
    1. Deeks JJ, Higgins JPT, Altman DG. In: Cochrane Handbook for Systematic Reviews of Interventions. Volume 5.10. Higgins JPT, Green S, editor. The Cochrane Collaboration; 2011. Chapter 9: Analysing data and undertaking meta-analyses.
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statis Med. 1998;17(24):2815–2834. doi: 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>;2-8.
    1. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care. 2003;19(4):613–623.
    1. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. doi: 10.1136/bmj.d4002.
    1. Sterne JAC, Egger M, Moher D. In: Cochrane Handbook for Systematic Reviews of Interventions. Volume 5.10. Higgins JPT, Green S, editor. The Cochrane Collaboration; 2011. Chapter 10: Addressing reporting biases. .
    1. The GRADE Working Group. List of GRADE working group publications and grants. .
    1. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. doi: 10.1186/1471-2288-7-10.
    1. Garritty C, Ansari M, Yazdi F, Singh K, Galipeau J, Pratt M, Young MM, Skidmore R, Lal A, Daniel R, Moher D, Grimshaw J. Evidence map of systematic reviews to inform the prevention, treatment, and/or harm reduction for illicit drug use. Report submitted to the Institute of Neuroscience, Addiction & Mental Health (INMHA) Canadian Institutes Health Res (CIHR) 2011. .

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever